Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Somatostatin (SRIF), a hypothalamic inhibitor of pituitary growth hormone (GH) and thyroid-stimulating hormone (TSH) secretion, binds to five distinct receptor (SSTR) subtypes. We therefore tested SSTR subtype-specific SRIF analogs in primary human fetal pituitary cultures (23-25-wk gestation) to elucidate their role in regulating human pituitary function. Using reverse transcription-PCR, mRNA expression of SSTR2 and SSTR5 were detected in fetal pituitary by 25 wk. SRIF analog affinities were determined by membrane radioligand binding in cells stably expressing the human SSTR forms. GH secretion was suppressed equally (40-60%, P < 0.005) by analogs preferential for either SSTR2 (IC50 for receptor binding affinity, 0.19-0.42 nM) or SSTR5 (IC50, 0.37 nM), and compounds with enhanced affinity for SSTR2 were more potent (EC50 for GH suppression, 0.05-0.09 nM) than Lanreotide (EC50, 2.30 nM) and SRIF (EC50, 0.19 nM). Similarly, analogs with high affinity for SSTR2 or SSTR5 decreased TSH secretion (30-40%, P < 0.005). However, prolactin was effectively inhibited only by compounds preferentially bound to SSTR2 (20-30%, P < 0.05). Luteinizing hormone was modestly decreased (15-20%) by SSTR2- or SSTR5-specific analogs. An SSTR5-specific analog also exclusively inhibited GH in acromegalic tumor cells. Thus, SRIF regulation of GH and TSH in primary human fetal pituitary cells is mediated by both SSTR2 and SSTR5, both of which are abundantly expressed by 25 wk. In contrast, suppression of prolactin is mediated mainly by SSTR2. These results indicate that SSTR5 is critical for physiologic regulation of GH and TSH. SRIF analogs with selective affinity for this receptor may therefore be more effective in the treatment of hormone-secreting pituitary adenomas.

[1]  J. Taylor,et al.  Receptor-specific somatostatin analogs: correlations with biological activity. , 1996, Metabolism: clinical and experimental.

[2]  J. Taylor,et al.  Improved analogs and novel delivery systems for somatostatin octapeptides. , 1996, Metabolism: clinical and experimental.

[3]  S. Melmed,et al.  Somatostatin Receptor Subtypes in Pituitary Tumors , 1996 .

[4]  S. C. Lee,et al.  Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol-primed pituitary cells. , 1996, The Journal of endocrinology.

[5]  A. O'Carroll,et al.  Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. , 1995, Endocrinology.

[6]  R. Day,et al.  Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. , 1995, Endocrinology.

[7]  T. Ohnishi,et al.  Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. , 1995, The Journal of clinical endocrinology and metabolism.

[8]  G. Bell,et al.  Molecular biology of somatostatin receptors. , 1995, Endocrine reviews.

[9]  T. Adrian,et al.  Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. , 1995, The Journal of surgical research.

[10]  A. Klibanski,et al.  Somatostatin receptor subtype gene expression in pituitary adenomas. , 1995, The Journal of clinical endocrinology and metabolism.

[11]  S. Melmed,et al.  Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. , 1995, The Journal of clinical investigation.

[12]  D. Hoyer,et al.  Classification and nomenclature of somatostatin receptors. , 1995, Trends in pharmacological sciences.

[13]  Y. Patel,et al.  Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. , 1994, Life sciences.

[14]  Kunihiko Hashimoto,et al.  Ribonucleic Acid Encoding Truncated Growth Hormone- Releasing Hormone Receptor in Human Pituitary Adenomas* , 1995 .

[15]  C. B. Srikant,et al.  Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). , 1994, Endocrinology.

[16]  S. Melmed,et al.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. , 1994, The Journal of clinical endocrinology and metabolism.

[17]  T. Reisine,et al.  Characterization of cloned human somatostatin receptor SSTR5. , 1994, Molecular pharmacology.

[18]  S. Seino,et al.  Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. , 1994, The Journal of clinical investigation.

[19]  C. B. Cohen,et al.  The future of the fetal tissue bank. The National Advisory Board on Ethics in Reproduction. , 1993, Science.

[20]  D. Hoyer,et al.  Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain , 1993, FEBS letters.

[21]  H. Imura,et al.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. , 1993, Biochemical and biophysical research communications.

[22]  L. Mahan,et al.  Characterization of cloned somatostatin receptors SSTR4 and SSTR5. , 1993, Molecular pharmacology.

[23]  M. Berelowitz,et al.  Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. , 1993, Biochemical and biophysical research communications.

[24]  G. Bell,et al.  Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. , 1993, Molecular pharmacology.

[25]  S. Law,et al.  Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. , 1993, The Journal of biological chemistry.

[26]  C. Goodyer,et al.  Effects of growth hormone (GH)-releasing factor and somatostatin on GH secretion from early to midgestation human fetal pituitaries. , 1993, The Journal of clinical endocrinology and metabolism.

[27]  L. Rohrer,et al.  Cloning and characterization of a fourth human somatostatin receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Greenwood,et al.  Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. , 1993, Biochemical and biophysical research communications.

[29]  B. Kacsoh,et al.  In vitro control of prolactin (PRL) and growth hormone secretion of neonatal rat pituitary glands: effects of ovine PRL, salmon calcitonin, endothelin-3, angiotensin II, bromocryptine and somatostatin. , 1993, Life sciences.

[30]  M. Berelowitz,et al.  Molecular cloning and functional expression of a brain-specific somatostatin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Seino,et al.  Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. , 1992, Molecular endocrinology.

[32]  D. Schoenfeld,et al.  Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. , 1992, The Journal of clinical endocrinology and metabolism.

[33]  C. Saper,et al.  Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. , 1992, The Journal of biological chemistry.

[34]  C. Saper,et al.  Differential expression of somatostatin receptor subtypes in brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  J. Bertherat,et al.  Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. , 1992, The Journal of clinical endocrinology and metabolism.

[36]  S. Law,et al.  Pharmacological properties of two cloned somatostatin receptors. , 1992, Molecular pharmacology.

[37]  S. Seino,et al.  Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Ridgway,et al.  Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. , 1992, The Journal of clinical endocrinology and metabolism.

[39]  A. Klibanski,et al.  Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. , 1991, The Journal of clinical endocrinology and metabolism.

[40]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[41]  S. Asa,et al.  Human fetal adenohypophysis: morphologic and functional analysis in vitro. , 1991, Neuroendocrinology.

[42]  G. Schettini Brain somatostatin: receptor-coupled transducing mechanisms and role in cognitive functions. , 1991, Pharmacological research.

[43]  J. Reubi,et al.  The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. , 1989, The Journal of clinical endocrinology and metabolism.

[44]  S. Lamberts The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. , 1988, Endocrine reviews.

[45]  W. Halliday,et al.  Human fetal adenohypophysis. Electron microscopic and ultrastructural immunocytochemical analysis. , 1988, Neuroendocrinology.

[46]  L. Frohman,et al.  Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. , 1988, The Journal of clinical endocrinology and metabolism.

[47]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[48]  S. Melmed,et al.  Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. , 1987, The Journal of clinical investigation.

[49]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[50]  W. Halliday,et al.  Human Fetal Adenohypophysis , 1986 .

[51]  B. Posner,et al.  Effect of insulin-like growth factors on human foetal, adult normal and tumour pituitary function in tissue culture. , 1986, Acta endocrinologica.

[52]  J. B. Martin,et al.  Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells. , 1985, Endocrinology.

[53]  P. Leroux,et al.  Ultrastructural autoradiographic localization of somatostatin-28 in the rat pituitary gland. , 1985, Endocrinology.

[54]  J. Reubi,et al.  High density of somatostatin receptors in pituitary tumors from acromegalic patients. , 1984, The Journal of clinical endocrinology and metabolism.

[55]  R. Evans,et al.  Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor , 1983, Nature.

[56]  J. Kieffer,et al.  The effect of somatostatin on the release of thyrotropin and its subunits from bovine anterior pituitary cells in vitro. , 1983, Endocrinology.

[57]  L. Frohman,et al.  Ectopic growth hormone releasing factor stimulates growth hormone release from human somatotroph adenomas in vitro. , 1983, The Journal of clinical endocrinology and metabolism.

[58]  L. Rees,et al.  Characterisation of immunoreactive somatostatin in human fetal hypothalamic tissue , 1983, Regulatory Peptides.

[59]  D. Moore,et al.  Human growth hormone DNA sequence and mRNA structure: possible alternative splicing. , 1981, Nucleic acids research.

[60]  N. Ling,et al.  Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion , 1981, Nature.

[61]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[62]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.